2020-2021
Pharmaceutical Industry Fellowship Program
Teva Pharmaceuticals / Rutgers University School of Pharmacy
Table of Contents

About Teva
Fellowship Overview
Fellowship Leadership
Program History
Applying
In a complex world, Teva’s mission is simple: to improve the lives of patients across the globe. We believe that everyone should have access to quality medicines whether it be for managing disease, fighting infections, or simply improving overall health.

We are proud that since Teva’s establishment in 1901, healthcare providers together with patients and caregivers have been using our accessible generic and innovative products. Today, our portfolio of around 3,500 products is among the largest of any pharmaceutical company in the world. Nearly 200 million people in 60 countries benefit from one of Teva’s quality medicines every day. We invest in research and development of generic medicines and biopharmaceuticals, carrying on the legacy of more than a century of finding new ways to help patients improve their lives. This defines our values as a company and characterizes how we do business and approach medicine.
Our Core Values

What we do every day matters. We’re applying passion and commitment to improve health. Our culture is about not only what we do, but how we do it.

Our values express what we believe in, they represent the best in us, and they guide us in all we do. Our mission and values were uncovered by our people. They evolved from stories that demonstrate our special spirit and culture and they represent those qualities that make us unique.

Leading the way

We aspire to be an industry leader and a mark of excellence in a constantly changing environment. We are passionate about being first to market and realizing opportunities. We believe that leadership happens with and through people.

Focus and Accountability

We are focused in everything we do. We define clear objectives and concentrate our efforts, attention and energy to deliver. We do what we say and we hold ourselves accountable for our actions and results.

Getting it done together

We all work for one company, Teva. By working together more effectively, in close collaboration and alignment, we tap into our full potential and drive our success.

Innovating Where We Create Value

We innovate to create value for patients, our partners in the healthcare system and our stakeholders. We constantly look for original and better ways to excel, creating solutions for current and future unmet needs.

Caring

We care. We care about the wellbeing of patients, caregivers and the communities we touch. We care about colleagues; creating a respectful, diverse and inclusive working environment.

Making our families proud

Teva improves health and contributes to people’s wellbeing each and every day. We do so by acting with integrity and maintaining the highest standards of quality, ethics and compliance.
Corporate Governance

Teva’s Corporate Governance policies provide the company with a comprehensive structure of best practices and high standards.

We maintain compliance with these policies, ensuring the company acts responsibly, ethically and lawfully. Key to this is the great emphasis we place on transparency throughout our business - from production and development to the way we manage our business.

Research & Development

We invest significantly into research and development to help our scientists effectively bring medicines to market so that our product portfolio addresses the changing needs and challenges of healthcare. It is this research that forms the engine for growth and development, not only for our company, but as part of our aspiration to improve health. In developing these treatments – in the fields of respiratory, pain, migraine and headache, movement and neurodegenerative disorders, oncology and more – our number one priority is improving the lives of patients around the world.

Teva’s Global Research & Development (R&D) organization is devoted to the development of new medicines, devices and combination products that provide meaningful therapeutic benefit to patients worldwide. Combining creativity, scientific rigor and our extensive knowledge on a broad range of technologies, our scientists, engineers, medical doctors and project leaders across the globe use their expertise to innovate novel biologics, biosimilars, small molecule specialty medicines, generics and over-the-counter therapies.

Generic Medicines

At Teva we believe that every one of us should have access to quality medicine that helps manage disease, fight infection, or simply improves overall health. That is why a substantial part of our business today and a significant portion of our research and development budget is focused on generic medicines.

Around 200 million people worldwide take one of our medicines every day. In the United States, where Teva is the leading generic pharmaceutical company, one out of every nine prescriptions is filled by a Teva product. In addition, many prescription medications made by other companies include active pharmaceutical ingredients produced by Teva.

With generic products, patients usually pay less while receiving the equivalent medicine to what is in the reference brand drug product. Generic medicines cost, on average, 80–85% less than the reference brand drug products. They account for 90% of prescription medicine in the United States, but they only make up 22% of total spending on prescription medicine in the United States.

Teva’s generic products support healthcare systems. Patients and healthcare providers in the United States saved more than $259 billion in the last decade by choosing Teva’s prescription generic medicine over more expensive brands.

Our global footprint is critical to ensuring that patients have access to our medicines. Teva has the largest supply chain of any pharmaceutical company and our network of nearly 40,000 employees and 65 global manufacturing sites work around the clock to make sure our medicines reach patients in over 60 countries across six continents. Every hour there is a plane in the air, a ship on the seas or a truck
About Teva

on the road delivering Teva's generic medicines to pharmacies and hospitals around the world.

We are committed to creating quality, affordable medicines for more people in more places around the world. Our scientists are currently developing over 1,000 generic medicines that aim to increase access to treatments that can improve patients' health and save healthcare providers billions.

Specialty Therapeutic Areas

While Teva focuses on developing, personalizing and making treatments accessible for patients across a wide range of therapeutic areas with our broad portfolio of generic medicines, we have several key areas of focus where our specialty research and development concentrates its efforts. There are treatments for respiratory, pain, migraine and headache, movement and neurodegenerative disorders, and oncology.

Biopharmaceuticals

Teva has made a strategic decision to invest in biopharmaceuticals as part of our growth plan for the future, and to help patients around the world. By making this long-term investment today, we are shaping Teva's path towards growth for the next decade.

In addition to investments in the development of innovative biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments. A focus on biosimilars is a natural progression for Teva following our role in the development of the generic medicine industry over the past 40 years. They combine our strength in generics with our knowledge of complex medicine. They offer value-based treatment that is potentially less expensive than the originator biologic but similarly effective.

Delivering on Our Mission

With our unique, integrated drug development model, Teva’s Global R&D organization helps propel the company’s mission to be a global leader in generics and biopharmaceuticals. From early development to commercial launch of small molecules, novel biologics and biosimilars, our “One Teva” R&D approach combines our strength in generics with our knowledge of innovative drug development. We leverage in-house expertise across our generics and specialty pipelines to unlock synergies and gain efficiencies that deliver high-quality, innovative treatments to patients.

As we work tirelessly to challenge unmet patient needs, our focus remains to understand current and future healthcare challenges and apply new technologies in an innovative and thoughtful manner to meet them. Through this company-wide commitment, we look to secure our position as a world leader in the development of healthcare solutions meeting the needs of patients today and tomorrow.

Learn more at www.tevapharm.com.
Follow us on Facebook and LinkedIn.
Pharmaceutical Industry Fellowship Program
Fellowship Overview

Teva Pharmaceuticals Regulatory Affairs Fellowship

The Teva Pharmaceuticals Regulatory Affairs Fellowship is a two-year fellowship – one year focused with U.S. Generics Regulatory Affairs and one year focused with U.S. Specialty/Branded Regulatory Affairs. The program will provide a unique opportunity for fellows to gain direct experience in the U.S. generic and specialty product approval processes all within one organization. Fellows will experience first-hand the differences, synergies and comparative approaches in these pharmaceutical pathways. The objective is for the fellow to become a meaningful contributor in the Generics or Global Specialty Regulatory Affairs organization at the conclusion of the fellowship.

This program provides opportunities for Rutgers fellows to develop into the future leaders of our global regulatory affairs team either in generics or branded products. The goal of the program is to
Fellowship Overview

find a balance between both structured learning and work experience. The program design would provide high-level knowledge building across the drug development continuum to help participants understand how all the constituent efforts result in the development and registration of safe, effective medications. Best of all, this program provides opportunities to establish working relationships with some of the most respected scientists and leaders in the generic and specialty (i.e. branded) sectors of the pharmaceutical industry.

During the two-year program, the fellows will learn through on-the-job experiences and professional development opportunities and will participate in two intensive one-year rotational assignments based at newly remodeled and state-of-the-art Teva facilities in New Jersey and Pennsylvania. (A hybrid work schedule combining in-office attendance and remote working may be instituted contingent on guidance from authorities and based on Teva standards to ensure maintained workplace safety and employee health.) Rotational assignments are designed to support various functions of the drug development spectrum, while stressing the development of leadership competencies.

One fellow will begin the rotation in Generics Regulatory Affairs based in Parsippany, New Jersey. The other fellow will begin their rotation in the Specialty (i.e. branded) organization based in West Chester, Pennsylvania. They will switch after one year of rotation. At the end of the rotation, the fellow will be responsible for a presentation to the Executive Committee and/or Key Personnel in the departments where they have worked.

The preceptor for Generics RA will be Kishore Gopu, Director, REMS Operations. The preceptor for Specialty RA will be Doug Harnish, VP, Regulatory Affairs.

Program Oversight and Management Executive Committee:

This is the team of senior leaders and executives which sponsors, funds and drives the program. These members are responsible for establishing the program’s management and includes business leaders from Global Regulatory Affairs and Human Resources.

Selection Team:
Recruiting for the program will be led by the Teva U.S. Talent Acquisition organization with members of Teva’s Executive Committee or their delegates as part of the selection team. Teva representatives would plan to participate in the FIND session (November) and ASHP Mid-Year Meetings (December), which are held annually (virtually if required because of the ongoing COVID crisis), for the duration of its participation in the RPIFP, beginning with the meetings in 2020.

Core Program Rotations:
The Executive Committee will decide at the beginning of the program the rotations, including content, outcomes and individuals responsible for supervising the rotations.

Mentoring:
Each fellow will have a formal preceptor who will act as their mentor assigned for 12 months, who is a member of the Executive Committee and would meet with them at least once a month. Additional opportunities for informal mentoring will also exist through interaction with members of the Teva team within and outside of Regulatory Affairs.
Scope of training and functional areas for the Fellow

The professional work assignments will include experiences within Regulatory Affairs, with exposure to shared service organizations as well as other business units within Teva.

Provide a high-level overview of Regulatory Affairs’ role in generic, specialty and biosimilar drug development and strategy, including ANDA, NDA, BLA, and sNDA submissions:
- Structure of Global Regulatory Teams
- Structure of project teams

In Generics RA, the fellow could spend the majority of time in one of the specialized areas, while exposed to the following regulatory functions:
- Chemistry, Manufacturing, and Controls (CMC)
- Labeling and Artwork.
- Regulatory Submissions management.
- Risk Evaluation and Mitigation Strategy (REMS) Operations.
- Each function’s contribution to strategy and marketing applications.

In Specialty Regulatory Affairs and Biosimilars, the opportunity allows the candidate to rotate through one of two therapeutic areas, with exposure to related functions based on the fellow’s interest and expertise:
- If there is a therapeutic area that has a particular need or a good learning opportunity, then the fellow could spend a majority of time in that area. The therapeutic areas encompass Neurology, Pain and Migraine, as well as Respiratory, Oncology and Internal Medicine.
- Exposure to related functions includes Chemistry, Manufacturing and Controls (for small molecules/biologics/combination products), as well as Labeling Development, and Advertising/Promotional Review.

Opportunities to meet and work with other departmental functions:
- Medical Affairs
- Clinical R&D
- Clinical Operations
- Commercial
- Government Affairs
- Legal
- Nonclinical Safety
- Pharmaceutical Development
- Pharmacovigilance
- Project leadership

Opportunities to tour local manufacturing facilities, laboratories, etc.

Fellowship Overview
Kishore Gopu, M.S., M.B.A., is the Director, Risk Evaluation and Mitigation Strategy (REMS) Operations. Kishore will be the preceptor for Generics RA. He has been with Teva since 2007 where he served in many departments, including: Regulatory Affairs, Commercial Operations, Patient Solutions, Market Access and Pharmacovigilance. Since joining Teva, Kishore has built the REMS department from the ground up and has been leading it for the last 8 years. Prior to joining Teva, he worked/consulted for many large corporations, including: Wyeth, Merck, and Johnson & Johnson. Kishore holds a B.E. in Electronics & Telecommunications, a M.S. in Computer Science from University of South Carolina, and a M.B.A. from Fairleigh Dickinson University.

Joyce Delgaudio is the Senior Director, Regulatory Affairs, where she is responsible for regulatory launch execution, labeling and drug listing, and certain post approval submissions. Joyce has over 30 years of experience in the pharmaceutical industry, primarily in the generic sector, having started out in the analytical laboratory (Research and Development as well as Quality Control) and then moving into Regulatory Affairs. Her past responsibilities included: regulatory strategy, submission and maintenance of FDA submissions developed both internally and externally. She has experience with a variety of dosage forms, including solid oral dose immediate and extended release, sterile injectables, nasal sprays, sterile ophthalmic, creams, liquids, ointments, drug device combos and complex drug products. Joyce is a graduate of the State University of New York at Stony Brook with a Bachelor of Science degree in Biology.
Fellowship Leadership

**John Derstine** is the Senior Director Regulatory Affairs Non-Sterile, Generics for Teva Pharmaceuticals, and has worked for Teva for over 21 years. The majority of John's pharmaceutical industry experience (19 years) has been in Regulatory Affairs with varying roles and responsibilities. Currently, John oversees both pre- and post-approval regulatory matters pertaining to primarily solid oral dose products developed/manufactured outside of North America. The main responsibilities of this role are managing and supporting the successful filings of new generic applications, ensuring timely approvals and compliance with Agency regulations. He holds a B.S. in Chemistry from Bloomsburg University (PA).

**Charlene Salmorin** is the Senior Director, Regulatory Affairs, US Generics, Labeling and Artwork Management Team at Teva and has over 30 years of experience in the Generic Pharmaceutical industry. Charlene has been instrumental in building, training, and leading the US Generics Labeling team since Teva acquired Actavis in 2016 and took on responsibility of building and leading the Artwork Management team in 2018. Charlene maintains right the first time approach related to labeling covered under new ANDA filings, new product launches, and in-line labeling/artwork changes, and continues to seek ways of meeting FDA's ever demanding labeling requirements leading to the timely implementation of process improvements while maintaining efficiencies. Her previous experience included positions of increasing responsibilities in several Pharma organizations, such as Actavis, G & W Laboratories, and Alpharma (Brand & Generic) and was responsible for managing teams in Regulatory Affairs (Labeling, Artwork, Drug Listing, and State Registrations), as well as Packaging and Quality Assurance.

**Apurva Pandya** is the Director of North America Regulatory Submission Management at Teva Pharmaceuticals. This global group has responsibility for compiling, dispatching and archiving submissions and ensuring those activities are captured in the appropriate systems. He joined Teva in April 2002. Apurva began his career in labeling before moving into Regulatory Submission Management. Apurva has over 15 years of Regulatory Submission and Information Management experience. He has implemented systems, technologies, and processes in Regulatory Submissions Management within Teva. He holds a B.S. in Computer Science from the New York Institute of Technology.

**Andrea Martens** is the Associate Director, Human Resources. Andrea is a Global HR Business Partner (HRBP) for 3 of Teva’s R&D business units: Global Clinical Internal and External, Global Generics Solid Oral Dosage, and the Global Project Leadership teams, a Global HRBP for the Global Marketing and Portfolio organization and is the HR Partner for the North America Generics Regulatory Affairs organization. Andrea is based in Parsippany, NJ and has over 20 years of HR experience in the pharmaceutical and consumer healthcare industries in numerous areas, including: HR strategic planning, organizational design, training and development, leadership coaching and mentorin, and performance management. In addition to Teva, Andrea has been a Global HRBP supporting R&D organizations at Organon, Schering Plough, Merck and GSK. She holds a Bachelor of Science degree in Elementary Education.
Fellowship Leadership

Preceptor

Doug Harnish is Vice President Specialty Regulatory Affairs and Therapeutic Area Head of Neurology, Pain and Migraine at Teva Pharmaceuticals. Doug will be the preceptor for Specialty RA Fellowship. For the first half of his career, he was in the R&D labs at Wyeth in both the Women’s Health and the Cardiovascular & Metabolic Disease Departments, as the Head of the Vascular Biology Group. He started his regulatory career at Pfizer supporting the Immunology and Autoimmunity programs as well as contributing to the Enbrel Advertising and Promotion team. He then joined Teva Pharmaceuticals where he now leads the Neurology, Pain and Migraine franchises and his group is comprised of Regulatory Strategy, Labeling, Operations and Advertising and Promotion.

Paula Hines, PhD, is Senior Director, Specialty Regulatory Affairs and Therapeutic Area Head of Respiratory, Oncology and Internal Medicine at Teva Pharmaceuticals. Paula started her biopharmaceutical career in monoclonal antibody research at The Wistar Institute, and later joined the FDA’s Center for Biologics Research and Review as a Staff Fellow in the Division of Hematology, Office of Blood Research and Review. Paula moved into the pharmaceutical industry starting with Pharmacia and Upjohn (now Pfizer), followed by CSL Behring for 13 years where she developed and implemented regulatory strategies in support of immunology, critical care, including hereditary angioedema, and cardiovascular indications for new biological (plasma-derived) products, recombinant products, and combination products. Paula first came to Teva in Jan 2016, as Director Regulatory Affairs in the CNS therapeutic area, where she led several of the early stage programs focused on psychiatry/schizophrenia, as well as early-stage and mature programs for neurodegenerative diseases. She later joined the Regulatory Affairs group at Merck in the therapeutic area of Infectious Diseases, followed by Jazz Pharmaceuticals in CNS/Sleep. Paula rejoined Teva in January 2020 and currently leads a regulatory team that includes Strategy, Labeling and Advertising and Promotion. She has a Bachelor of Science degree in Microbiology from Pennsylvania State University and a PhD in Physiology from Thomas Jefferson University.

S Prasad Peri, PhD, is a Senior Director, Global Specialty Regulatory Affairs Chemistry Manufacturing and Controls (CMC) and is responsible for managing the Teva’s branded assets within the US region. He has been with Teva for the past four and half years leading the CMC related activities encompassing small molecules, biologics, combination products and devices including software. Some of the recent activities include approvals of combination products such as ProAir Digihaler, ArmonAir Digihaler, QVAR Redihaler, Ajovy injection, and Austedo. Before joining Teva, he was with Merck Pharmaceuticals leading the combination products team for about one and a half years. Prior to joining Merck, he worked at the Food and Drug Administration as a Branch Chief responsible for managing the review aspects of CMC sections of new drug application (NDAs), investigational new drug applications (INDs), inter center consults and drafting guidances and other related activities. He holds a PhD in Pharmaceutical Chemistry and a Bachelors of Pharmacy.
Michael Kauer, M.S., is the HR Director for R&D. He joined Teva in 2015 to lead the North America Leadership & Development (L&D) function within HR. In that role, he collaborated closely with colleagues from around the world in L&D, broader HR, and the business to provide strategic direction and deep subject matter expertise in organizational effectiveness, leadership development, and various areas of talent management (e.g., performance management, talent review & succession, workforce performance, etc.) Based in West Chester, PA, Michael provides support to Global Specialty Regulatory Affairs and Biosimilars Regulatory Affairs, US Specialty R&D, and the Combination Products & Devices and Specialty Project Leadership, which is located in West Chester. Before joining Teva, Michael worked at Covance, a leading contract research organization, where he led a global team of performance consultants working closely with R&D leaders, and also had responsibility for the global performance management function and global Employee Engagement strategy and survey. He spent the first part of his career in management consulting at Accenture and Deloitte, and he has been working in the pharmaceutical industry for more than 20 years. Michael holds an M.S. in Industrial/Organizational Psychology.
Michael Banks, MSc, is Senior Vice President Regulatory Affairs Research and Development for Teva Pharmaceuticals. Mr. Banks is globally responsible for all Regulatory Affairs activities for Teva. He has nearly 30 years of industry experience having previously worked in different Regulatory and Medical Affairs roles for IVAX, Sandoz and Astra Pharmaceuticals. He was Chair or Deputy-Chair of Medicines for Europe (MFE) Regulatory and Scientific Affairs Committee; Chair of the MFE working group with the European Medicines Agency (EMA) on Centralized Procedures (CP) for Generics and is a member of the International Generic and Biosimilars Association’s Scientific Committee. Michael is a Fellow of the Royal Society of Medicine and a Fellow of the Organization for Professionals in Regulatory Affairs.

Javier Monvoisin is the VP of Global Regulatory Operations (GRO) leading the global Regulatory Submissions Management (RSM) and Regulatory Information Management (RIM) teams in Global Regulatory Affairs (GRA). He is based in Harlow, UK and his leaders and team members are based in Harlow; Parsippany, NJ; Zagreb, Croatia; and Mumbai, India. Javier joined Teva in 2007 and has 22 years in the pharmaceutical industry, inclusive of prior experience with Merck and Ranbaxy. His roles at Teva have included regional positions, such as the European Regulatory Affairs Documents Management Systems leader from 2007 to 2010 and the EU RIM leader from 2010 to 2013. Javier has been managing global roles in GRA since 2013, beginning with leading the global RIM team until 2015 and the global RSM team from 2015 until 2018 when he moved to his current position. He reports directly to Michael Banks as the SVP of GRA in his GRO VP role. Javier is a member of The Organisation for Professionals in Regulatory Affairs (TOPRA) and earned his BS degree in Biomedical Science & Pharmacology from the University of Bradford in the UK.

Valerie Mulligan is Vice President, Global Specialty Regulatory Affairs for Teva Pharmaceuticals, and is responsible for managing Teva’s branded assets around the globe. Products include the company’s flagship product COPAXONE® for multiple sclerosis, as well as AJOVY® for migraine, AUSTEDO® for Huntington’s Disease/Tardive Dyskinesia, and AZILECT® for Parkinson’s. Valerie started her R&D career over 30 years ago with Bristol-Myers Squibb in Ireland, moving to the US to join the start-up company of McNeil Specialty Products (a division of Johnson and Johnson (J&J)). From there, she joined Ethicon (a device company within J&J) to lead their QA Engineering department. Subsequently, Valerie moved to Neose Technologies, a small-cap biotechnology company, where she rose to SVP, Regulatory Affairs and Quality. Valerie joined Teva in 2010 to lead the Women’s Health Regulatory Affairs organization, and has increased her portfolio responsibilities over the past decade to add global CMC, international markets and therapeutic area responsibilities. Valerie represents Teva as a member of the Regulatory Steering Groups of both PhRMA (US) and EFPIA (EU). Valerie holds a B.Sc (Hons) and graduate H. Dip, Ed. from National University of Ireland, Dublin.
Fellowship Leadership

Scott D. Tomsky, M.S., is Vice President, North America, Regulatory Affairs, Generics for Teva Pharmaceuticals, and has been in the pharmaceutical industry for over 20 years. Scott joined Teva Pharmaceuticals in July 2013 and is responsible for the oversight of Regulatory Affairs matters for Teva Generics, North America with main objectives being the successful filings of new generic applications, ensuring timely approvals, and compliance with Agency regulations. He holds a B.S. in Biology from the College of NJ, and a M.S. in Quality Assurance and Regulatory Affairs from Temple University. Prior to joining Teva, Scott held leadership positions at Johnson and Johnson Consumer Products, Ranbaxy and McNeil Consumer Healthcare in Formulation and Regulatory Affairs. He has also had responsibility for Pharmacovigilance.

Cory Wolhbach is Global Vice President, Biosimilars Regulatory Affairs at Teva Pharmaceutical Industries Ltd. In this role, Cory leads Teva's regulatory strategy for biosimilar medicines. Before leading the biosimilars regulatory affairs team, Cory spent over eight years in regulatory affairs at Teva developing and gaining approval of complex generic drug products, generic drug-device combination products, sterile injectable generic drugs and biologics/biosimilars. Prior to Teva, Cory also held regulatory affairs positions at MedImmune and Sanofi Pasteur. Cory holds a B.S. in Biology from Muhlenberg College in Pennsylvania.

Jeff Harvey is the Senior Director, Global HR Business Partner (HRBP), for 4 Teva Research & Development (R&D) business units: Global Regulatory Affairs; Specialty R&D; Combination Products & Devices and Semisolids & Inhalation; and Generics R&D Steriles. Jeff is based in West Chester, PA and has 30 years of HR experience inclusive of 23 years in the pharmaceutical industry between Teva and Zeneca/AstraZeneca. He has been working with R&D groups for 14 years and has managed global leadership roles in HR since 2003. As the GRA HRBP, Jeff is a matrix leader collaborating with HR Partners in North America, Europe, Israel, India and Japan to deliver people initiatives designed to drive performance in the GRA business. These activities include but are not limited to change management; leadership development, leadership coaching; employee development; management training; performance management & reward; employee engagement; talent acquisition; and recognition. Jeff was involved in initiating Teva’s RA Fellowship partnership with Rutgers in 2014 and holds the program in high regard. Jeff holds a Bachelor of Science degree in Communications from Clarion University of PA. He has also held memberships in Recruiting Roundtable as the former Staffing Director at AstraZeneca and the HR Planning Society (HRPS).
In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 21 companies within the pharmaceutical and biopharmaceutical industries and over 250 fellows annually.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the Institute for Pharmaceutical Industry Fellowships to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

• provide leadership and administrative support;
• promote quality, communication, and scholarly activity; and
• arrange specialized fellowship training opportunities within the pharmaceutical and biopharmaceutical industries.
Program History

Recently in 2018, our program has expanded to offer interdisciplinary fellows’ training by adding select physician fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy and Dr. Lesley Fierro the Director for the Institute for Pharmaceutical Industry Fellowships.

More than 1000 post-doctoral fellows have completed the RPIF Program, most of whom are pursuing influential and rewarding careers in the pharmaceutical and biopharmaceutical industries throughout the US and abroad. The RPIF Program has preceptors/mentors from industry who share their knowledge and experiences with the fellows through an intense but closely guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industries and the fellow’s functional area.

Professional Development Series

All fellows gather at Rutgers once monthly as a group to participate in the Professional Development Day (PDD) Series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of fellows and are designed to enhance the fellows’ presentation skills, emotional intelligence, promote connectivity and a sense of community among fellows from different companies and disciplines, develop new skill sets under the guidance of external trainers, and provide general knowledge about various aspects of drug development and issues facing the pharmaceutical and biopharmaceutical industries.

The fellows learn from each other through individual and group presentations and debates on topics and issues related to the pharmaceutical and biopharmaceutical industries. This dynamic forum provides an opportunity for open discussion and debate among fellows, Rutgers faculty, and company preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success; professional writing, presentations, meeting facilitation, negotiating, influencing, networking, and conflict resolution skills; giving and receiving feedback; and business and dining etiquette). Other PDD guest speakers include senior industry executives, patient advocacy groups, and successful RPIF Program alumni who share their insights and experiences. Importantly, PDDs provide an excellent opportunity for fellows to interact with each other and develop lasting personal friendships and a strong professional network of fellows, faculty, alumni, and other industry executives.
Rutgers, The State University of New Jersey, with approximately 70,875 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The Ernest Mario School of Pharmacy is part of Rutgers Biomedical and Health Sciences, the only state school of pharmacy in New Jersey, with approximately 1,300 students in its Doctor of Pharmacy program. The Rutgers Ernest Mario School of Pharmacy is located on the University’s main science and technology campus in Piscataway, New Jersey. Because of its close proximity to the nation’s leading pharmaceutical and biopharmaceutical companies, the Ernest Mario School of Pharmacy and the RPIF Program are uniquely capable of providing fellows with advanced training in the pharmaceutical and biopharmaceutical industries.

Program History

Key Program Features

**Family of Leading Companies**
Partners include several of the top 21 global pharmaceutical and biopharmaceutical companies.

**Outstanding Alumni Track Record**
Over 1000 alumni hold prominent positions at many leading companies.

**Strong Network**
Over 250 fellows each year develop valuable, lasting connections with each other, alumni, preceptors and faculty.

**The Pathway to Industry**
Since 1984, the Rutgers program has been nationally recognized, trusted, and proven as the pathway to industry for pharmacists.

**Enhanced Career Path**
Increasingly challenging assignments build depth of experience and enhance the potential for an accelerated career path.

**Rigorous Academic Component**
Rutgers affiliation provides academic and professional development opportunities.

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy

Lesley Fierro, M.S., PharmD.
Fellowship Director
Rutgers Pharmaceutical Industry Fellowships
Pharmaceutical Industry Fellowship Program
Applying

Application Process and Eligibility Requirements:

Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE accredited institution before July 1 of the fellowship term. Due to the ongoing pandemic, participation in PPS/ASHP is required. The PPS Portal will be necessary to request an interview with positions of interest. Interested individuals may submit their application materials (curriculum vitae, three letters of recommendation and a letter of intent) beginning September 2020 by visiting our website at: pharmafellows.rutgers.edu

All application materials must be submitted electronically to the RPIF Website, along with requesting an interview via the PPS Portal.

How to Apply:

<table>
<thead>
<tr>
<th>Required Items</th>
<th>Deadline*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curriculum Vitae (CV)</td>
<td>November 6th</td>
</tr>
<tr>
<td>Letter of Intent (LOI)</td>
<td>November 6th</td>
</tr>
<tr>
<td>Letters of Recommendation (LORs)</td>
<td>December 4th</td>
</tr>
</tbody>
</table>

*This is a rolling submission. Applicants are strongly encouraged to submit application materials as soon as possible to request an interview.

Please address your Letter of Intent & Letters of Recommendation to:

Joseph A. Barone, Pharm.D., F.C.C.P.
Dean and Professor II
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020